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Abstract Purpose To evaluate clinical and angio-
graphic differences in patients with Vogt-Koyanagi-
Harada (VKH) disease during the early 4-month
treatment phase with high- or medium-dose systemic
corticosteroid therapy. Methods VKH patients treated
at the Centre for Ophthalmic Specialized Care, Lau-
sanne, Switzerland (n = 4), or the Department of
Ophthalmology, Tokyo Medical and Dental Univer-
sity, Tokyo, Japan (n = 5), underwent a pre-treatment
indocyanine green angiography (ICGA) and a follow-
up ICGA four months after treatment began. Lausanne
patients received high-dose, systemic corticosteroid
therapy, with or without immunosuppressive therapy.
Tokyo patients received medium-dose systemic corti-
costeroid therapy that included 3 days of intravenous
pulse methylprednisolone. ICGA signs including cho-
roidal stromal vessel hyperfluorescence and leakage,
hypofluorescent dark dots (HDD), fuzzy vascular
pattern of large stromal vessels and disc hyperfluores-
cence were retrospectively compared. Results The pre-
treatment ICGA demonstrated that each of the nine
patients had choroidal inflammatory foci, as indicated
by HDD. At 4-month follow-up, clinical and fluores-
cein findings had improved almost equally in both
groups. HDD had resolved in the Lausanne group but
persisted in the Tokyo group. Sunset glow fundus
occurred in three of the Tokyo patients and none of the
Lausanne patients. Conclusions Submaximal doses of
inflammation suppressive therapy are sufficient to
suppress clinically apparent disease but not the under-
lying lesion process. This explains the propensity for
sunset glow fundus in seemingly controlled disease.
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Introduction
Vogt-Koyanagi-Harada (VKH) disease is a bilateral
granulomatous uveitis that initially presents as a
panuveitis or more frequently as a predominantly
posterior uveitis with papillitis and exudative retinal
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detachments. There is increasing evidence that the
disease is an autoimmune Th1 type reaction directed
against proteins related to stromal choroidal melano-
cytes [1]. Therefore, the primary inflammatory events
occur at the level of the choroidal stroma, making it a
primary stromal choroiditis [2]. The inflammatory
reaction in VKH is sometimes mild and remains
subclinical and confined to the choroid, and diagnosis
is difficult without sensitive investigational tests of
the choroid. Most of the time, however, the inflam-
matory reaction is hyperacute going beyond the
choroid and involving secondarily adjacent structures
such as the retinal pigment epithelium and the retina.
Although these structures are involved only as a
consequence of primary choroidal inflammation, they
are accessible to clinical examination and will render
the disease clinically apparent, showing the classical
signs of multiple exudative retinal detachments and
papillitis. These clinical signs respond to massive
inflammation suppressive therapy, which is agreed to
be necessary to control the hyperacute phase of the
disease [3–5].
A consistent finding in a large portion of VKH
patients is the development of sunset glow fundus,
even after the clinical disease appears to be under
control [6, 7]. Development of sunset glow fundus in
the absence of manifest clinical disease suggests a
silently progressing disease and indicates that the
post-acute treatment regimen may not be optimal.
Until indocyanine green angiography (ICGA) became
available, there were no methods sensitive enough to
detect subtle choroidal inflammation, and ultrasonog-
raphy was the imaging method used for VKH disease
[8]. However, in order to detect choroidal involve-
ment with ultrasonography, a certain degree of
choroidal thickening is necessary, which is the case
in established VKH but not in subclinical or early
stages of the disease. Ultrasonography is not sensitive
enough to detect early and isolated choroidal foci
(granuloma) or reappearance of foci in subclinical
recurrent VKH. In contrast, ICGA is sensitive enough
to detect small choroidal inflammatory foci and to
provide information about the choriocapillaris circu-
lation and inflammation of choroidal stromal vessels
[9]. Thus, ICGA is currently the most appropriate
method for investigating choroidal diseases, as it is
sensitive enough to demonstrate minimal and, often,
subclinical changes in the choroid [10–12]. More-
over, in cases of suspected VKH disease that do not
have an acute onset or that are seen at a later stage,
when suboptimal therapy has already been intro-
duced, or that do not exhibit a complete set of signs,
diagnosis of VKH becomes more difficult, and the
diagnostic contribution of ICGA is especially useful
[13–17].
In the present study, we compared VKH patients
from two treatment centres where the standard of
care differed significantly. Early therapeutic inter-
ventions (first week) were comparable in both
centres and controlled acute clinical disease. How-
ever, after the early phase of therapy (first week),
treatment strategies differed markedly in the two
centres. At one centre, therapy consisted of persis-
tent high oral doses of corticosteroids slowly
tapered, with or without adjuvant immunosuppres-
sive therapy; and in the other centre, therapy
consisted of medium doses of more rapidly tapered
corticosteroids. We compared ICGA results at
presentation and at follow-up after four months of
differential therapeutic regimens.
Patients and methods
Patients
Patients who were diagnosed with VKH disease
according to clinical findings, having presented with
an initial acute inflammatory episode between
December 1998 and May 2006, had an ICGA before
inflammation suppressive therapy was introduced and
had an ICGA at follow-up after 4 months of
treatment at the Centre for Ophthalmic Specialized
Care, Lausanne, Switzerland, or the Department of
Ophthalmology, Tokyo Medical and Dental Univer-
sity, Tokyo, Japan. The patients who had a history of
penetrating ocular trauma, surgery preceding the
onset, or clinical or laboratory evidence of other
entities of uveitis, were excluded.
Treatment regimens differed significantly in
both centres. In Lausanne, high dose inflammation
suppressive therapy consisted of pulse intravenous
methylprednisolone (500–1,000 mg/day) for 3 days
followed by high levels of oral corticosteroid therapy
(initial dose 1.0–1.5 mg/kg/day prednisone) with a
slow tapering schedule for 4 months, or oral cortico-
steroids only, at the same dose and tapering schedule.
For patients who had severe inflammatory findings
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such as bullous retinal detachment and swollen optic
disc, cyclosporine was added during the first month of
the regimen. In Tokyo, treatment consisted of pulse
intravenous methylprednisolone (500–1,000 mg/day)
for 3 days followed by a lower dose of oral cortico-
steroids (initial dose 0.6–0.8 mg/kg/day prednisone)
for the following 4 months. Standard ophthalmologic
examination, including best corrected visual acuity,
slit-lamp examination of the anterior segment, fundus
examination with fundus photography, laser flare
photometry, and, in cases of suspected ciliary body
effusion, ultrasound biomicroscopy, were performed.
In addition, a neurological examination that included a
spinal tap to search for monopleiocytosis in the
cerebrospinal fluid, a hearing examination, and a skin
examination were performed.
Fluorescein angiography and ICGA were per-
formed according to a standard protocol prior to
introduction of inflammation suppressive therapy
and, 4 months after initiation of treatment.
ICGA results were correlated with clinical findings,
fluorescein angiograph results, and dose of inflam-
mation suppressive therapy. Particular attention was
given to four major ICGA signs classically recorded,
including early choroidal stromal vessel hyperfluo-
rescence and leakage, hypofluorescent dark dots
(HDD), fuzzy pattern of large stromal vessels, and
disc hyperfluorescence (see below for details).
Standard ICGA protocol for inflammatory
diseases
A standard ICGA protocol was used [18]. A Topcon
50IA (Topcon, Tokyo, Japan) fundus camera cou-
pled to an Imagenet digitizing system was used in
Lausanne. In Tokyo, the Topcon 50IA camera was
coupled to an analog video system, and images were
later digitized using a commercially available dig-
itizing system (WinTV-PVR-2; Hauppauge
Computer, Taipeh, Taiwan). The angiography pro-
cedure consisted of three phases. The early, 0–3 min
phase demonstrates superimposed retinal and cho-
roidal large vessels and incipient exudation of the
dye through the choriocapillaris into the choroidal
stroma. The intermediate phase, from *8 min,
demonstrates maximum choroidal stromal back-
ground indocyanine green (ICG) fluorescence. The
late phase, from *20 min, depending on fundus
pigmentation, demonstrates washout of the dye from
the general circulation, with the large choroidal
vessels appearing dark against the background
stromal fluorescence.
ICGA signs
ICGA signs in VKH disease have been characterized
and are currently used for the initial evaluation and
follow-up of VKH disease [18–20]. We chose to
evaluate ICGA signs that were estimated to be the
most consistent, most useful, and easiest to evaluate
and record for follow-up purposes, as previously
described [18, 21]. The signs were:
1. Early choroidal stromal vessel hyperfluorescence
and leakage, which suggests severe choroidal
stromal inflammatory vasculopathy. It appears
early in angiography and indicates the severity of
the choroidal inflammatory vasculopathy that, in
later phases, gives way to diffuse choroidal
hyperfluorescence.
2. Hypofluorescent dark dots (HDD) which are
thought to correspond to choroidal foci (granu-
loma), which are the most consistent and easily
recorded angiographic signs, allowing semi-
quantitative assessment of choroidal inflamma-
tory activity. HDD were evaluated using an
arbitrary score from 0 to 4 based on the extension
and number of dots, as previously described [22].
3. Fuzzy vascular pattern of large stromal vessels;
the fuzzy pattern indicates diffuse inflammatory
vasculopathy of stromal vessels. Its presence is
apparent during the intermediate phase and, in
the late phase, gives way to diffuse stromal
hyperfluorescence.
4. Disc hyperfluorescence. The optic disc is dark
and nonfluorescent in normal ICGA. Disc
hyperfluorescence indicates severe disease and
usually regresses rapidly with initial induction
therapy. Therefore, it is a valuable marker for
response to initial high-dose anti-inflammatory
therapy.
Statistical analysis
The data are expressed as the mean ± SD. Data were
analyzed and compared using Mann–Whitney U test,
and were considered statistically significant with
P \ 0.05.
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Results
Patients, clinical features, and fluorescein
angiography results
Nine patients (four in Lausanne, five in Tokyo)
fulfilled the inclusion criteria. They underwent ICGA
prior to initiation of inflammation suppressive ther-
apy. At least one additional ICGA was performed
after 4 months of therapy. In Lausanne, all patients
had monthly ICGA for 4 months. Lausanne patients
were females. Of the five Tokyo patients, two were
female and three were males. The mean age of
patients was lower in the Lausanne group
(32.0 ± 6.1 years) compared to the Tokyo group
(45.6 ± 15.1 years), but this difference was not
significant. All patients classified as incomplete
VKH of the revised diagnostic criteria at presenta-
tion, as they also include chronic signs and do not
allow a diagnosis of complete VKH at disease onset
[23]. Patient and disease characteristics are shown in
Table 1. The groups did not differ significantly on
any variables at presentation. For all patients, the
inflammatory episode marked the onset of VKH. The
disease was bilateral with papillitis and lymphople-
iocytosis in the cerebrospinal fluid for all nine
patients, and multiple exudative retinal detachments
were present in three of the Lausanne patients and
four of the Tokyo patients. Uveitis had an initial
anterior component and presented as a panuveitis in
three Lausanne patients and four Tokyo patients.
Fluorescein angiographs in the Lausanne group were
characterized by bright disc hyperfluorescence in all
four patients (8 eyes) and signs of exudative retinal
detachments and subretinal fluid in three patients (5
eyes). In the Tokyo group, disc hyperfluorescence
was observed in five patients (10 eyes), and exudative
retinal detachments with pooling of subretinal fluid
was observed in four patients (8 eyes). The delay
from the onset of symptoms to initiation of initial
high-dose inflammation suppressive therapy was
evaluated in both groups, and the mean delay
was 4.5 ± 3.1 weeks in Lausanne patients and
2.4 ± 0.6 weeks in the Tokyo patients, indicating
that diagnostic delay is longer in countries where
VKH occurs sporadically, but this difference was not
significant. Intravenous pulse methylprednisolone
therapy (500–1,000 mg/day for 3 days) was admin-
istered in two Lausanne and five Tokyo patients.
Mean oral averaged prednisone dose/kg/day during
the 4-month treatment period was significantly higher
(0.75 ± 0.2 mg/kg/day; initial dose 1.0–1.5 mg/kg/
day) for the Lausanne group compared to the Tokyo
group (0.36 ± 0.02 mg/kg/day; initial dose 0.6–
0.8 mg/kg/day; p = 0.039). Two of the four Lau-
sanne patients also received cyclosporine therapy.
The mean averaged daily dose per month was
1.04 ± 0.37 mg/kg/day for the Lausanne group ver-
sus 0.52 ± 0.07 mg/kg/day for the Tokyo group for
the first month and 0.55 ± 0.15 mg/kg/day versus
Table 1 Demographics
and disease characteristics
in the Lausanne and Tokyo
groups
Lausanne Tokyo
Sex 4 F 2 F, 3 M
Mean age 32.0 ± 6.1 years 45.6 ± 15.1
Bilaterality 4/4 patients 5/5 patients
CSF monopleiocytosis 4/4 patients 5/5 patients
Hearing disorders 0/4 patients 1/5 patients
Time from symptoms to treatment 4.5 ± 3.1 weeks 2.4 ± 0.6 weeks
Initial anterior uveitis 3/4 patients 4/5 patients
Exudative retinal detachments 3/4 patients 4/5 patients
Papillitis 4/4 patients 5/5 patients
Sunset glow fundus at 4 months 0/4 patients 3/5 patients
Integumentory findings at 4 months 0/4 patients 1/5 patients
VAOD initial 0.80 ± 0.28 0.94 ± 0.36
VAOS initial 0.77 ± 0.29 0.90 ± 0.24
VAOD final 1.44 ± 0.12 1.44 ± 0.12
VAOS final 1.31 ± 0.24 1.44 ± 0.12
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0.20 ± 0.04 for the fourth month, respectively.
Details of treatment regimen during the 4-month
period are shown in Fig. 1.
Mean best corrected visual acuity for Lausanne
patients was 0.78 ± 0.3 (8 eyes) at presentation and
1.37 ± 0.18 (8 eyes) after 4 months. Values for the
Tokyo patients were 0.92 ± 0.32 at presentation and
1.44 ± 0.12 (10 eyes) at 4 months, indicating that
both groups had complete visual recovery after
4 months. Fundus lesions recovered and fluorescein
angiography signs were considered normal in all nine
patients at 4 months. However, at 4 months, three of
the five Tokyo patients had mild to moderate sunset
glow fundus. Sunset glow fundus did not occur in any
of the four Lausanne patients.
One of the Tokyo patients developed a hypergly-
cemia after corticosteroid therapy was initiated, but
the serum glucose level was decreased within normal
limits by a diet. None of the Lausanne patients
showed any side effects of inflammation suppressive
therapy during observation.
ICGA data
All the patients had consistent ICGA findings at
presentation. Early hyperfluorescent leaking stromal
vessels were seen in three of the Lausanne patients,
and the mean time to resolution of this sign was
1.88 ± 0.76 months. The sign was not detected in
any of those patients at 4 months. All five Tokyo
patients showed this ICGA sign at presentation, with
a larger number of vessels involved compared to the
Lausanne group (Fig. 2a). At the 4-month ICGA
follow-up, the sign was still present in two of the
Tokyo patients (Fig. 2b).
HDD were semi-quantitatively evaluated with an
arbitrary score from 0 to 4. HDD intensity and score
were similar for the two groups at presentation in
the ICGA intermediate phase (3.5 ± 0.53 for the
Lausanne group and 3.7 ± 0.42 for the Tokyo group;
Fig. 3a, c). At 4 months, HDD was more than 90%
resolved in all patients of the Lausanne group, with a
mean time to resolution of 2.62 ± 1.25 months and a
decrease in HDD score from 3.5 ± 0.53 to
0.25 ± 0.46; (Fig. 3b). The situation was different
for the Tokyo group, in which HDD persisted at
nearly identical intensity and score (3.7 ± 0.42 at
presentation and 3.25 ± 0.46 at 4 months), although
ophthalmic findings improved almost equally in both
groups (Fig. 3d).
(m
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0.8
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1.2
Treatment month
0
0.2
0.4
0.6
1 2 3 4
: p< 0.05
Fig. 1 Graph showing chronology of the two oral prednisone
treatment regimens
Fig. 2 Early hyperfluorescent leaking stromal vessels. Numer-
ous hyperfluorescent posterior pole stromal vessels prior to
treatment (a). For two Japanese patients, this sign persisted
after 4 months of treatment (b)
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Fuzzy vascular pattern of large stromal vessels was
identical in the two groups at presentation. It resolved
completely in the Lausanne patients (Fig. 4a, b) at a
mean of 2.12 ± 0.85 months, and it persisted in the
Tokyo patients (Fig. 4c, d). The only ICGA sign that
resolved completely in both groups was disc
hyperfluorescence. It was the first ICGA sign to
respond to treatment in the Lausanne group, with a
mean resolution time of 1.25 ± 0.86 months. It was
resolved in the Tokyo group at 4 months (Fig. 5a, b).
As mentioned in the ‘‘Patients and methods’’
section, we did not evaluate all ICGA signs. Most
Fig. 3 Hypofluorescent dark dots (HDD). Numerous well
demarcated dark spots are seen in the intermediate angio-
graphic phase. Also, note the fuzzy choroidal stromal vessels,
the pattern of which cannot be distinguished (a Swiss patient, c
Japanese patient). In Swiss patients, HDD resolved after
1 month of sustained high-dose corticosteroid therapy (b)
whereas HDD and fuzzy vessel appearance were persisted in
Japanese patients at 4 months after treatment (d)
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patients presented some degree of delay in choroidal
filling in the early angiography phase before treat-
ment was initiated.
Discussion
Onset of VKH disease is characterized by a prodro-
mal stage during which the Th1 autoimmune reaction
against melanocyte-associated antigens is believed to
cause silently developing lesions within the choroid.
When adjacent, functionally important structures,
such as the optic disc and the macula are involved,
the disease becomes clinically apparent [24]. This
phase of VKH disease is typically managed with
high-dose pulse intravenous corticosteroids or
high-dose oral corticosteroids followed by oral
corticosteroids [25]. Although that strategy is usually
successful in controlling acute disease and restoring
visual function, it does not appear to influence long-
term outcomes [26]. A recent study that evaluated
data from several centres showed that pulse intrave-
nous corticosteroid therapy did not influence long-
term outcome of the disease [27].
Final outcomes for VKH disease seem to depend on
long-term treatment strategies. To date, long-term
management of VKH disease is not clearly defined and
varies across centres and cases, including the dose of
oral corticosteroids after the initial (first week) high-
dose inflammation suppressive treatment, the tapering
protocol, and the suitability of concomitant immuno-
suppressive therapy. Data are accumulating which
suggest that current long-term management strategies
for VKH disease are unsatisfactory, and several lines of
Fig. 4 Fuzzy pattern of larger stromal vessels in a Lausanne
patient. Prior to treatment no stromal vessels can be recognized
(a Swiss patient, c Japanese patient). After treatment, a normal
vascular pattern of stromal vessels can be seen in the Swiss
patient (b), whereas the situation did not change 4 months after
treatment in Japanese patient (d)
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evidence indirectly show that the post-acute level of
inflammation suppressive therapy is often suboptimal.
Sunset glow fundus was shown to develop in most
reported series, even in seemingly controlled VKH
disease, and is more prominent in VKH disease with
clinically persistent inflammatory signs [6, 7, 28, 29].
This suggests that VKH disease progressed despite
seemingly sufficient treatment. Our ICGA compari-
sons of two treatment groups show that choroidal
disease was ongoing in patients that received less oral
prednisone treatment in the 4 months post-acute
treatment period. To the best of our knowledge, ours
is the only study to provide direct evidence that
submaximal treatment during the post-acute period of
VKH disease is associated with persistent choroidal
inflammatory activity, despite apparent control of
clinical signs. On the other hand, sufficient high-dose
post-acute therapy completely suppressed choroidal
inflammatory disease within 2–4 months. Our results
also demonstrate that clinical examination and fluo-
rescein angiography are not sufficient, but ICGA is
required for precise monitoring of inflammatory
activity especially at the choroidal level.
A dose of 0.36 mg/kg/day is not sufficient to
suppress all choroidal inflammatory signs and a dose
as high as 0.75 mg/kg/day appears to be required
during the first 4 months of treatment. In the present
study, we evaluated the effects of inflammation
suppressive therapy in four European patients after
4 months of therapy. We determined that the level of
therapy necessary to achieve similar control of the
disease in Japanese patients may have to be even
higher, as the amount of choroidal pigment is
probably higher in Japanese patients compared to
European patients. However, all the European
patients were from southern Europe and had dark
complexions. In fact, one of those patients was of
American Indian descent. Nevertheless, the present
findings justify a controlled, ICGA monitored study
comparing Japanese patients receiving standard treat-
ment (i.e., medium-dosed post-acute oral
corticosteroid therapy) to Japanese patients with
high-dose oral post-acute corticosteroid therapy, with
concomitant immunosuppressive therapy when
indicated.
The present study did not provide information
about an acceptable tapering course. Previously
published data show that by monitoring therapy taper
with ICGA subclinical choroidal recurrence of VKH
disease can be detected [21]. Since ICGA is a
sensitive method for investigating choroidal inflam-
matory lesions, it should probably be the method of
Fig. 5 Disc hyperfluorescence. Prior to treatment, the optic disc is hyperfluoresscent and HDD are present (a). After treatment, the
disc is no longer fluorescent and HDD have resolved (b)
48 Int Ophthalmol (2010) 30:41–50
123
choice with which to precisely adjust inflammation
suppressive therapy in VKH disease.
There is an increasing number of studies that
support our finding that deleterious outcomes are
associated with insufficient long-term inflammation
suppressive therapy [30, 31]. This is further sup-
ported by recent studies which indicate that
additional immunosuppressive therapy seems to be
beneficial [30, 31]. With these results in mind, it
seems advisable to prevent unfavorable outcomes in
VKH patients. For this purpose, clinical signs and
fluorescein angiography are no longer the only
methods for monitoring treatment efficacy. Now,
efficacy can be more precisely evaluated with ICGA,
allowing preventive therapy adjustments during the
tapering phase of treatment [21].
To summarize, suboptimal inflammation suppres-
sive therapy in the post-acute period of VKH disease
may be sufficient to suppress clinically apparent
disease, but it does not suppress the underlying lesion
process, which explains the development of sunset
glow fundus in seemingly controlled disease. Based
on our findings, we recommend high-dosed, ICGA-
guided therapy for ocular VKH disease.
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